Recently, at the “Riding the Waves, Setting Sail” 2025 Medical Device Park Tour Shanghai Station event hosted by Arterial Network, Ms. Xie Jing, Commercial Director of CCRC MedTech, was invited as a distinguished guest to participate in the panel discussion titled “How Can Medical Device Enterprises Trapped in the Centralized Procurement ‘Bloodbath’ Stabilize Their Core and Build Confidence?” This invitation was based on CCRC MedTech’s profound insights in clinical value assessment and commercialization strategies for medical devices, particularly its extensive practical experience in addressing volume-based procurement (VBP) for high-value consumables. As the sole representative from a CRO institution in the roundtable discussion, Ms. Xie Jing provided constructive suggestions on full lifecycle management for innovative medical devices from the perspective of third-party professional services, offering highly valuable strategic insights for China’s medical device industry at this critical juncture of innovation-driven development.
Pathways to Breakthrough Under Normalized Centralized Procurement
Against the backdrop of deepening centralized procurement policies for medical devices, Ms. Xie Jing pointed out during the discussion: *”Centralized procurement is reshaping the industry’s competitive landscape. Enterprises must shift from pure price competition to value competition. Building core competitiveness through product innovation, clinical differentiation, and lean operations is the long-term strategy to meet the challenges of centralized procurement. In this transformation of the medical device industry, CROs must also redefine their value and positioning.”
1. Evolving from Service Providers to Strategic Enablers
As a leading domestic clinical trial service provider, we have long moved beyond simply executing clinical trials. We are building a full lifecycle service system covering “R&D-Registration-Clinical-Post-Market.” Particularly in the field of innovative medical devices, we have established a think tank team composed of seasoned regulatory experts, clinical specialists, and statisticians, capable of providing enterprises with end-to-end solutions from product initiation to commercialization. This deep empowerment is helping an increasing number of innovative companies overcome development bottlenecks.
2. Building an Industry-Level Clinical Research Platform
CCRC MedTech has established a clinical research service network covering 30+ cities nationwide and maintains close collaborations with top-tier medical institutions and investigators. This not only significantly enhances the efficiency of clinical trials but, more importantly, establishes a standardized clinical evaluation system tailored to different types and stages of medical devices.
3. Fostering an Ecosystem of Collaborative Innovation
As a bridge connecting enterprises, hospitals, and regulatory agencies, we are actively promoting the establishment of a Medical Device Clinical Research Alliance. This alliance will integrate the strengths of stakeholders across the industry chain, enabling collaborative innovation in key areas such as clinical demand mining, trial protocol design, and data management and analysis.
4. A Clinical Engine Empowering Chinese Medical Devices on the Global Stage
As a key facilitator in the globalization of Chinese medical devices, CCRC MedTech has established specialized regulatory teams covering critical markets such as Europe, the U.S., Southeast Asia, and the Middle East, enabling customized global registration pathways for innovative medical devices. At the same time, we deeply engage with leading international clinical experts to feed global cutting-edge clinical demands back to domestic R&D, truly realizing the leap from “Made in China” to “Innovated in China.” To date, we have successfully supported over 20 domestic innovative medical device products in entering international markets, with three receiving FDA Breakthrough Device designation. These achievements reinforce our belief that on the global stage of medical innovation, Chinese medical devices are transitioning from followers to leaders—and CCRC MedTech will continue to play the critical role of a “global clinical partner.”
Under the centralized procurement landscape, clinical value will become the core competitiveness of medical device enterprises, and CROs should not remain mere bystanders or basic service providers. As a leader in clinical research services, we are committed to opening all our capabilities and resources to collaborate with industry stakeholders in driving China’s medical device sector toward high-quality development. We believe that only when the entire industry ecosystem thrives can every participant achieve greater growth.
